years, many centers have also employed peripheral blood stem cell transplantation (PBSCT). Most peripheral blood stem cell transplants have been autologous, 5-9 although Accelerated granulocyte and platelet recovery following peripheral blood stem cell transplantation (PBSCT) are allogeneic peripheral blood stem cell transplants have also been studied.
nosis of non-Hodgkin's lymphoma. Of the 10 autologous an additional serum sample collected. All sera were stored at Ϫ70°C until assayed. PBSCT patients, four patients had a diagnosis of Hodgkin's disease and six patients had a diagnosis of non-Hodgkin's lymphoma. PBSCT patients had more advanced stage of Antibody assays disease than the ABMT patients, nine PBSCT patients (90%) and 10 ABMT patients (59%) had either stage III Total binding anti-HIB antibody was measured by radioimor IV at the time of diagnosis. More patients in the PBSCT munoassay (RIA) using a standard Food and Drug Admingroup (50%) as compared to the ABMT group (18%) had istration protocol with tritiated polyribosylribitol phosphate tumor involvement of the bone marrow. Limited regional (provided by Dr Porter Anderson, University of Rochester, radiotherapy was given to one PBSCT patient (10%) and NY, USA). The RIA was standardized using the Center for six AMBT patients (35%) within 3 months of transplanBiologic Research and Review standard serum pool with tation. None of the differences in clinical characteristics of an assigned value of 70 g/ml. IgG and IgM anti-HIB antithe two groups was statistically significant as noted in body concentrations were measured by enzyme-linked Table 1 .
immunosorbent assay (ELISA) using HIB oligosaccharide Patients who survived without relapse until at least 3 coupled to human albumin (provided by Dr Porter months post-transplant were enrolled in the study. Patients Anderson) and standardized using a serum reference pool who relapsed, died, missed immunizations, or were lost to with assigned values of 27.2 g/ml for HIB IgG and follow-up after 3 months post-transplant were included in 1.62 g/ml for HIB IgM. IgG and IgM anti-tetanus toxoid the analysis until the time that these events occurred. Two antibody concentrations were measured by ELISA as pre-PBSCT patients had not reached the 24 month time-point viously described. 20 Total serum IgG and IgM concenat the time of analysis. The study was approved by the trations at 12 and 24 months post-transplant were determInstitutional Review Boards of both participating hospitals ined by ELISA using goat anti-human IgG and IgM (Tago, and informed consent was obtained from each enrolled Burlingame, CA, USA) and goat anti-human IgG and IgM patient.
alkaline phosphatase conjugates (Tago) as described previously. 20 All serum samples for a given time-point from both transplant groups were measured in the same assays Collection of PBSC and bone marrow to reduce effects of interassay variation. Autologous PBSC were collected by three to six aphereses performed during the rapid rise in blood counts following Statistics myelosuppressive chemotherapy. Four PBSCT patients also received GM-CSF mobilization therapy. A Fenwall CSData organization and analysis were performed by the 3000 Plus cell separator (Fenwall Laboratories, Dearfield, PROPHET system, a national computer system sponsored IL, USA) with a granulocyte chamber was used for autoby the Chemical/Biological Information Handling Program mated isolation of mononuclear cells after bone marrow of the National Institute of Health (Bethesda, MD, USA). harvest or PBSC collection. Mononuclear cells were then Logarithms of the antibody concentrations were used for cryopreserved in dimethyl-sulfoxide (DMSO) using a constatistical calculations. Antibody concentrations that were trolled rate liquid nitrogen freezer. The number of monobelow the limit of assay sensitivity were assigned values nuclear cells pre-freezing per kilogram of patient's lean of one half the lower limit. 12 months, and nine at 24 months.
Median days to achieve 16 (10-27) 21 (11-42) ANC у0.5 ϫ 10 anti-HIB antibody concentrations were similar for patients in the PBSCT group as compared with patients in the mg/dl (284-1840) respectively in the ABMT group.
In contrast, total serum IgM concentrations were signifi-ABMT group at each measured time-point (data not shown). cantly lower in the PBSCT group compared with patients in the ABMT group at 12 and 24 months. Geometric mean
The frequency of patients with presumed protective concentrations of total anti-HIB antibody was also compared total serum IgM concentrations (95% confidence interval) at 12 months after transplant were 28.2 mg/dl (4.70-169) for the two transplant groups. A concentration of total anti-HIB antibody of у1.00 g/ml is considered to be predicin the PBSCT group compared with 100 mg/dl (15. in the ABMT group (P = 0.007). At 24 months, geometric tive of long-term protection. 21 More patients in the PBSCT group had protective levels of total anti-HIB antibody folmean total serum IgM were 42.4 mg/dl (11.2-161) in the PBSCT group compared with 152 mg/dl (62.1-370) in the lowing immunization compared with patients in the ABMT group. At 6 months, 12 months, and following the 12 month ABMT group (P = 0.001).
dose, 44, 25, and 75% of patients in the PBSCT group had protective antibody concentrations compared to 24, 17 and Antibody responses to HIB-conjugate vaccine 43% respectively of patients in the BMT group. The frequency of patients with protective antibody concentrations PBSCT recipients had higher anti-HIB antibody concentrations at all measured time-points following transplanat 24 months declined to 60% in the PBSCT group and 11% in the ABMT group. Following the 24 month dose, tation compared to ABMT recipients. Geometric mean IgG anti-HIB antibody concentrations as measured by ELISA the frequency of patients protected increased to 80% in the PBSCT group and 44% in the ABMT group. The differwere significantly higher in the PBSCT group at 24 months (11.3 g/ml vs 0.93 g/ml, P = 0.051) and following the ences in the frequency of patients protected in each group were not statistically significant at any of the measured 24 month immunization (66.2 g/ml vs 1.30 g/ml, P = 0.006). The difference in IgG anti-HIB antibody contime-points. centrations trended towards significance at 12 months and following the 12 month dose ( Table 2) . Similar results were Antibody responses to tetanus toxoid vaccine noted for total anti-HIB antibody as measured by RIA with significantly higher geometric mean antibody concenPatients in the PBSCT group also achieved higher IgG antitetanus toxoid antibody concentrations following immunitrations at 24 months post-transplantation (8.30 g/ml vs 0.22 g/ml, P = 0.01) and following the 24 month immunization as compared to those in the ABMT group (Figure 2) . Geometric mean IgG anti-tetanus toxoid antibody concenzation (74.0 g/ml vs 1.14 g/ml, P = 0.02) (Figure 1) . Measurements of HIB antibody by RIA and ELISA assays trations were significantly higher in the PBSCT group at 24 months post-transplantation (182 g/ml vs 21.6 g/ml, were highly correlated at each measured time-point (r = 0.51 to r = 0.96). IgM concentrations to HIB were also P = 0.039) and trended toward significance at 12 months and following the 24 month immunization ( Table 2) . compared between the two transplant groups before and after HIB-conjugate immunization. Geometric mean IgM
Although IgG anti-tetanus toxoid antibody concentrations compared with patients in the ABMT group at 24 months and post 24 months transplantation, multiple linear regression analyses were performed to examine the effect were higher in the PBSCT group, all patients in each group had IgG anti-tetanus toxoid antibody concentrations above of selected clinical variables on IgG anti-HIB and antitetanus toxoid antibody concentrations at these time-points. the presumed protective level of у 0.01 IU/ml (equivalent to 0.43 g/ml in our assay) at all measured time-points
The influence of these variables on total serum IgG and IgM concentrations at 12 and 24 months after transplanpost-transplantation. 22 Similar to HIB IgM antibody results, IgM anti-tetanus toxoid antibody concentrations were not tation were also examined. The variables included in the analyses were: type of transplant, age, gender, underlying significantly different between the two transplant groups both before and following immunizations. diagnosis, number of relapses, stage of disease, tumor involvement of the marrow, GM-CSF mobilization therapy, number of prior chemotherapy regimens, pre-transplant Variables affecting total serum immunoglobulins and radiation therapy, post-transplant radiation therapy, and antigen-specific antibody concentrations after total number of mononuclear cells infused. transplantation PBSCT was independently significantly associated with higher total anti-HIB antibody concentrations at 24 months Because of the significant differences in antigen-specific antibody concentrations of patients in the PBSCT group (partial correlation coefficient 0.662, P = 0.009) and post 24 months (partial correlation coefficient 0.611, P = 0.019), memory cells infused. Both the carrier protein for the HIBconjugate vaccine, diphtheria toxoid, and the tetanus toxoid and with higher IgG anti-HIB antibody concentrations at 24 months (partial correlation coefficient 0.531, P = 0.034) vaccine are administered as routine childhood vaccines. Thus the harvested peripheral blood and marrow would and following the dose at 24 months (partial correlation coefficient 0.695, P = 0.005). PBSCT was also indepencontain memory B and T cells for both these proteins. The representation of memory B cells and T cells in peripheral dently associated with higher IgG anti-tetanus toxoid antibody concentrations at 24 months (partial correlation coefblood as compared to marrow is not clearly defined. However, the total number of mononuclear cells/kg infused was ficient 0.556, P = 0.072). In addition, younger age of recipients was independently associated with higher IgG at least seven-fold greater in the PBSCT group than the number infused in the ABMT group. Thus we suggest that anti-tetanus toxoid antibody concentrations at 24 months and post 24 months transplantation. No other variables were more memory B and/or T lymphocytes were likely to be infused in the PBSCT group as compared to the marrow consistently associated with antigen-specific antibody concentrations.
recipients. We also noted that the geometric mean total serum IgM Finally, PBSCT was independently significantly associated with lower total serum IgM concentrations at 12 months concentrations were significantly lower at 12 and 24 months post-transplant in the PBSCT patients. One pre-(partial correlation coefficient 0.569, P = 0.007) and 24 months (partial correlation coefficient 0.771, P = 0.001) vious study has reported a similar percentage of patients following PBSCT or ABMT had low total serum IgM conafter transplantation. None of the variables was consistently independently associated with total serum IgG concencentrations; however, the time after transplantation when the measurements were determined was not equivalent trations.
between the transplant groups. 18 Our finding will need to be confirmed and the significance of lower total serum IgM is unknown. It is possible that PBSCT results in fewer IgM Discussion naive B cells being transferred compared to marrow transplantation. Primary antibody responses would then be PBSCT results in more rapid reconstitution of hematopoiesis as compared to bone marrow transplantation. However impaired despite enhanced secondary antibody responses. We doubt any clinical significance of this finding. immune reconstitution has been less well studied. [14] [15] [16] Descriptions of reconstitution of lymphocyte subsets over
The small number of patients in this report is a limitation. One reassuring fact was that antibody responses were time and in vitro functional assays, as well as immunoglobulin concentrations, have been published. 14, 18, 19, 23 These enhanced for both vaccines studied. In addition, our groups were not randomized due to obvious practical considerinitial studies evaluate reconstitution following PBSCT and make comparisons to those previously reported for marrow ations. The predominant indication for PBSCT during the study period was the inability to obtain adequate marrow. recipients. In general these studies have indicated similar immune reconstitution for PBSCT recipients and recipients We would not expect PBSCT patients to be 'better responders' as these patients were at a more advanced stage of autologous marrow cells. 14, 18, 19 However, these studies are difficult to interpret as the patient populations are hetof disease. Finally, we included patients who received both PBSC and marrow in the PBSCT group. This decision is erogeneous, the numbers of patients studied are small and the comparisons are made using in vitro assays or lymphosupported by other investigations which have demonstrated that hematopoietic reconstitution of patients who receive cyte phenotype analysis. In addition, these comparisons are not direct correlates of protection from infectious pathoboth PBSC and BM is similar to patients who receive PBSC only. 24, 25 gens. We therefore examined functional humoral immunity following transplantation using antigen-specific responses In summary, increased antibody responses to HIB-conjugate and tetanus toxoid vaccines administered after transto immunizations. The protective correlates of responses to these vaccines are well established and commonly plant were documented in PBSCT patients as compared to ABMT patients. We speculate that PBSCT patients have employed to determine immune function for immunodeficient patients.
enhanced immune reconstitution and are at less risk for infections. Of note, our study examined T cell-dependent Ten patients who received PBSCT and 17 patients who received ABMT were immunized with HIB-conjugate and antibody responses and not cellular immune function. The effect of PBSCT on reconstitution of antigen-specific cytotetanus toxoid vaccines following transplantation at 3, 6, 12 and 24 months. The PBSCT patients had consistently toxic lymphocytes (CTL) will need to be defined although it is likely that increased numbers of CTLS were also transhigher antibody concentrations compared to the ABMT group after the first three doses. The differences in IgG ferred. Different cytokine and chemotherapy mobilization techanti-HIB antibody reached significance following the final immunization at 24 months (P = 0.006). For IgG antiniques, positive selection of CD34 ϩ cells for infusion, ex vivo expansion of CD34 ϩ cells, and the use of umbilical tetanus toxoid antibody, the PBSCT patients had higher concentrations before the final dose at 24 months and folcord blood cells are all being actively investigated for transplantation. [24] [25] [26] [27] [28] [29] Our data suggest that immune reconstitution lowing that dose (P = 0.039, P = 0.104 respectively).
Our study demonstrates that antigen-specific responses will likely be affected by these manipulations. Our results may also have importance for tumor vaccine studies in the are enhanced in PBSCT patients as compared to autologous marrow recipients. We speculate that the mechanism for transplant setting. We speculate that enhanced tumor vaccine responses would be seen in PBSCT compared to autothis difference relates to the number of antigen-specific 
